Alkermes
design goals differentiated receptor agonist to address unmet patient needs robust efficacy convenient dosing favorable tolerability increased wakefulness once daily oral medication duration improved cataplexy control dose to allow for hours wakefulness with no later insomnia reduced risk of heart rate and blood pressure effects seen with stimulants | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
136 of 144
Related slides by other companies
Exscientia
Investor Presentation
November 2023
highly differentiated inhibitor | Exscientia
Exscientia
Results
November 2023
highly differentiated inhibitor a | Exscientia
Exscientia
Investor Presentation
October 2023
highly differentiated inhibitor | Exscientia
Apollo Global Management
Investor Presentation
November 2022
is differentiated by design | Apollo Global Management
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io